we aimed to investigate treatment response, survival profiles, safety profiles, and predictive factors of drug-eluting beads-transarterial chemoembolization(deb-tace) with callispheres® microspheres (csm) in treating chinese hepatocellular carcinoma (hcc) patients.
a total of 66 hcc patients about to receive deb-tace with csm therapy were consecutively enrolled in this prospective cohort study. treatment response was recorded. besides, progression-free survival (pfs) and overall survival (os) were also recorded. all adverse events including pain, nausea, vomiting, fever, and liver function damage were recorded during hospitalization.
37.9% of patients achieved complete response (cr) and 81.8% of patients achieved an objective response rate (orr). for survival, mean pfs and os were 13.7 (11.7-15.8) months and 18.8 (95% ci: 16.3-21.2) months, respectively. multivariate logistic regression analysis revealed that a number of nodules ≥2 was an independent factor for worse cr; moreover, multivariate cox's regression analysis disclosed that largest sample size ≥5 cm was an independent factor for shorter pfs, and child-pugh b and bclc stage b/c were independent predictive factors for unfavorable os. as to aes, numbers of patients suffered liver function damage, pain, nausea, vomiting, and fever were 29 (43.9%), 27 (40.9%), 22 (33.3%), 13 (19.7%), and 37 (56.1%), respectively.
37.9%的患者达到完全缓解(cr)，81.8%的患者达到客观缓解(orr)。生存方面，pfs和os分别为13.7个月(95%ci:11.7-15.8)和18.8个月(95%ci:16.3-21.2)。多因素logistic回归分析显示，结节数≥2是cr较差的独立预测因素；多变量cox回归分析显示，最大结节≥5cm是pfs较短的独立预测因素，child-pugh b级和bclc b/c期是os不佳的独立预测因素。aes方面，肝功能损害、疼痛、恶心、呕吐、发热患者数分别为29例(43.9%)、27例(40.9%)、22例(33.3%)、13例(19.7%)、37例(56.1%)。
drug-eluting beads-transarterial chemoembolization with csm is an effective and tolerated treatment for chinese hcc patients, and number of nodules≥2, largest nodule size≥5 cm, child-pugh stage b, and bclc stage b/c correlates with unfavorable prognosis.
对于中国hcc患者，csm载药微球经动脉化疗栓塞是一种有效且耐受性良好的治疗方式，并且结节数≥2、最大结节≥5 cm、child-pugh b级、bclc b/c期与预后不良相关。